We just need your registered Email Id
to sent your password reset
instructions.
You're doing something extraordinary. We'll keep you in the loop with our latest news and special offers. Please update your profile on a regular basis and be an active community member. Let others know we exist and together we can move medicine forward.
You are now registered within Modern Trials network. If we receive patient inquires within your zip code we will let you know. Be on the look out for an E-Mail from our team.
| NCT Id | NCT04107675 |
|---|---|
| Title | A Safety Study of Liposomal Cyclosporine A to Treat Bronchiolitis Obliterans Syndrome Following Allogeneic Hematopoietic Stem Cell Transplant |
| Condition | Bronchiolitis Obliterans |
| StudyType | Interventional |
| Organization | Breath Therapeutics Inc. |
| Sponsor/Collaborators | Breath Therapeutics Inc. |
| Status | Not yet recruiting |
| Gender | All |
| AgeGroup | Adult Older Adult |
| Location (with distance) |
|
| Description | This is a Phase II prospective, multi-center, single-blind, randomized clinical trial of safety in the treatment of BOS 1 in adult recipients of an allogeneic hematopoetic stem cell transplant. Twenty-four patients are planned for enrollment. The clinical trial will be conducted in approximately 20 centers in Germany, France, and Spain. Patients will be randomly allocated 1:1:1 to receive either L-CsA (10 mg bid or 5 mg bid) plus Standard of Care, or liposomal placebo plus Standard of Care. Investigational Medicinal Product will be administered for up to 12 weeks. |
Your interest has been recorded and our team is working hard for you. We will contact you with further steps.